- Home
- GRFX vs ABVC Comparison
GRFX vs ABVC Comparison
Compare GRFX & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRFX
- ABVC
- Stock Information
- Founded
- GRFX 1981
- ABVC 2015
- Country
- GRFX Hong Kong
- ABVC United States
- Employees
- GRFX N/A
- ABVC N/A
- Industry
- GRFX
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- GRFX
- ABVC Health Care
- Exchange
- GRFX Nasdaq
- ABVC Nasdaq
- Market Cap
- GRFX 18.1M
- ABVC 16.7M
- IPO Year
- GRFX N/A
- ABVC N/A
- Fundamental
- Price
- GRFX $0.75
- ABVC $1.21
- Analyst Decision
- GRFX Hold
- ABVC
- Analyst Count
- GRFX 1
- ABVC 0
- Target Price
- GRFX N/A
- ABVC N/A
- AVG Volume (30 Days)
- GRFX 19.1K
- ABVC 203.5K
- Earning Date
- GRFX 01-01-0001
- ABVC 04-30-2025
- Dividend Yield
- GRFX 0.03%
- ABVC N/A
- EPS Growth
- GRFX N/A
- ABVC N/A
- EPS
- GRFX N/A
- ABVC N/A
- Revenue
- GRFX $24,184,100.00
- ABVC $508,383.00
- Revenue This Year
- GRFX N/A
- ABVC $735.18
- Revenue Next Year
- GRFX N/A
- ABVC N/A
- P/E Ratio
- GRFX N/A
- ABVC N/A
- Revenue Growth
- GRFX N/A
- ABVC 1904.43
- 52 Week Low
- GRFX $0.71
- ABVC $0.40
- 52 Week High
- GRFX $2.75
- ABVC $1.40
- Technical
- Relative Strength Index (RSI)
- GRFX 33.58
- ABVC 62.38
- Support Level
- GRFX $0.93
- ABVC $1.01
- Resistance Level
- GRFX $1.12
- ABVC $1.36
- Average True Range (ATR)
- GRFX 0.11
- ABVC 0.10
- MACD
- GRFX -0.01
- ABVC 0.02
- Stochastic Oscillator
- GRFX 0.00
- ABVC 72.92
About GRFX Graphex Group Limited each representing 20
Graphex Group Ltd is engaged in the sale of graphene products. It operates in three segments namely, the Graphene Products Segment includes Processing and sale of graphite and graphene-related products; the Landscape Architecture Design Segment includes Providing landscape architecture design; and the catering business focuses on the operation of restaurants. The company derives the majority of its revenue from the sale of graphene products segment.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.